SEQUENTIFY


Associated tags: Weizmann Institute of Science, Genomics, NGS, DNA, AI, Fine chemical, Vaccine, AML, Synthetic biology, Virology, Research, Entrepreneurship, DNA sequencing, Hospital

Locations: ISRAEL, WISCONSIN, UNITED STATES OF AMERICA

Sequentify Awarded Grant by Israel Innovation Authority for Infectious Disease Sequencing Panel

Retrieved on: 
Thursday, January 11, 2024
DNA, Infection, Diagnosis, IIA, Research, Massive parallel sequencing, Pharmaceutical industry

REHOVOT, Israel, Jan. 11, 2024 /PRNewswire/ -- Sequentify, a company specializing in DNA sequencing technology, has been granted funding by the Israel Innovation Authority (IIA). This grant, contributing to a project totaling $1.3 million, supports the development of Sequentify's targeted sequencing panel for infectious disease research. The panel aims to provide a culture-free, next-day solution for sequencing pathogens, focusing on pathogen diagnosis and antibiotic resistance surveillance.

Key Points: 
  • Sequentify Secures Funding to Advance Culture-Free, Rapid Pathogen Sequencing Technology
    REHOVOT, Israel, Jan. 11, 2024 /PRNewswire/ -- Sequentify , a company specializing in DNA sequencing technology, has been granted funding by the Israel Innovation Authority (IIA).
  • This grant, contributing to a project totaling $1.3 million, supports the development of Sequentify's targeted sequencing panel for infectious disease research.
  • The panel aims to provide a culture-free, next-day solution for sequencing pathogens, focusing on pathogen diagnosis and antibiotic resistance surveillance.
  • Sequentify's development of this sequencing panel reflects its ongoing commitment to contributing valuable tools for infectious disease research and management.

Stanford to use Sequentify kits for Hematological Malignancies NGS Sequencing

Retrieved on: 
Wednesday, November 8, 2023
Regenerative medicine, Acute myeloid leukemia, DNA sequencing, Entrepreneurship, Research, Genomics, NGS, Somatic mutation, Virology, AI, Synthetic biology, National Democratic Front of the Philippines, Automation, AML, Weizmann Institute of Science, DNA, Stanford University School of Medicine, Fine chemical

Founded in 2021, Sequentify democratizes genomics by providing DNA library preparation for Next Generation Sequencing (NGS) and AI software that enables fast, cost-effective and automated sequencing.

Key Points: 
  • Founded in 2021, Sequentify democratizes genomics by providing DNA library preparation for Next Generation Sequencing (NGS) and AI software that enables fast, cost-effective and automated sequencing.
  • Sequentify's NGS products are based on its InfiniSeq proprietary platform and include cancer diagnostics, carrier screening, virology and other applications.
  • Tom Fleischer, Co-Founder and CEO of Sequentify added: "We are excited to work with Stanford Medicine, a world leading research institute and hospital, on implementing cost effective and high throughput NGS sequencing for myeloid conditions."
  • The patent-pending InfiniSeq technology is adjustable to most sequencing machines and fits into any lab workflow.

Sequentify collaborates with Yeda, the commercial arm of the Weizmann Institute, under an NIH grant for evaluating the effect of clonal hematopoiesis on cognitive impairment and kidney function decline

Retrieved on: 
Monday, October 31, 2022
CSO, Hospital, Privacy, CKD, Weizmann Institute of Science, Genomics, University, NGS, Government budget balance, MDS, Research, CMML, Patient, JMML, Oncology, Doctor of Philosophy, Population, Technology, MPN, RUO, Prevalence, NIH, WIS, Yeda, AML, Medical device, Vaccine, Medical imaging, Myeloid tissue

REHOVOT, Israel, Oct. 31, 2022 /PRNewswire/ -- Sequentify announced its collaboration with Yeda, the commercial arm of the Weizmann Institute of Science (WIS) and NIH, as part of a grant to sequence over 6,000 patients using the Sequentify Myeloid NGS panel, offering cost-effective, high throughput NGS sequencing at scale.

Key Points: 
  • Sequentify's Myeloid NGS genetic panel enables diagnostics, screening and prediction of blood-derived cancers such as MDS, AML, MPN, CMML and JMML.
  • This means fewer employees are needed, less training required, the pricing supports mass market implementations.
  • Furthermore, the technology enables scalability from sequencing a few patients to performing whole population screening, keeping costs low and turnover time fast.
  • "The ability to perform targeted sequencing across large cohorts easily and cost-effectively using Sequentify's technology now enables affordable performance of such research."

Democratizing Genomics, Sequentify Raises $7M to Enable DNA Sequencing at Scale

Retrieved on: 
Tuesday, May 10, 2022
Weizmann Institute of Science, Laboratory, COVID-19, Democratization of technology, Omicron, Software, NGS, Epigenomics, Liquid biopsy, Virology, Synthetic biology, Delta, Hospital, DNA, Genomics, OurCrowd, DNA sequencing, Solution, Technology, CEO, Entrepreneurship, AI, Vaccine, Fine chemical

REHOVOT, Israel, May 10, 2022 /PRNewswire/ -- Sequentify, a Weizmann Institute of Science spinoff, enables fast and focused DNA sequencing. It combines tools from the synthetic biology and AI software fields to enable rapid targeted DNA sequencing. Sequentify exits stealth mode with $7M in raised funds led by Israel's most active venture firm, OurCrowd. The funds will be used to accelerate R&D, delivery, and go-to-market plans for the company.

Key Points: 
  • It combines tools from the synthetic biology and AI software fields to enable rapid targeted DNA sequencing.
  • Sequentify exits stealth mode with $7M in raised funds led by Israel's most active venture firm, OurCrowd.
  • Sequentify democratizes genomics by providing DNA library preparation for Next Generation Sequencing (NGS) and AI software that enables fast, cost-effective and automated sequencing.
  • Sequentify enables DNA screening at scale with the goal of making genomics as common and affordable as testing for blood counts."